Want to see JP:3349 full AI Analyst Report?
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥5,615.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥490.73B
Enterprise Value¥493.59B
Total Cash (Recent Filing)¥57.04B
Total Debt (Recent Filing)¥49.96B
Price to Earnings (P/E)15.6
Beta-0.25
Next Earnings
Jul 13, 2026EPS Estimate
117.37Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)390.85
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)415.91
Revenue Forecast (FY)¥1.18T
Bulls Say, Bears Say
Bulls Say
Diversified Retail Drugstore Model & Nationwide FootprintA broad product mix (prescription, OTC, health/beauty, daily necessities) and a nationwide store network create durable revenue diversification and stable foot traffic. Scale supports procurement, cross-selling, and resilience to localized demand shocks over the next several months.
Consistent Revenue Growth And Stable MarginsSustained revenue growth accompanied by stable gross and net margins indicates effective pricing and cost management. This pattern supports reliable earnings power, enabling predictable operating cash generation and planning for gradual store expansion or product investment.
Solid Balance Sheet And Strong ROELow leverage and strong equity metrics provide financial flexibility to fund growth or absorb shocks without urgent refinancing. Robust ROE reflects efficient capital use, underpinning the firm's ability to invest in stores, logistics, or IT over the medium term.
Bears Say
Negative Free Cash Flow TrendPersistent negative free cash flow undermines the translation of accounting profits into usable cash, constraining internal funding for capex, store openings, or debt reduction. Over months this can force higher external financing or defer investments, raising structural risk.
Increasing Total Debt Over TimeA trend of rising total debt, even from a low base, reduces headroom and could raise interest costs or covenant risk if cash generation weakens. If FCF remains negative, higher leverage can impair strategic flexibility and increase vulnerability to macro stress.
Slight Decline In EBIT MarginA falling EBIT margin signals creeping cost or competitive pressure that may erode profitability over time. If sustained, margin compression would reduce cash available for expansion or debt servicing and requires operational or pricing responses to restore resilience.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥5615.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥490.73B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 13, 2026 which is in 13 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Apr 13, 2026. The company reported ¥102.19 earnings per share for the quarter, beating the consensus estimate of ¥100.689 by ¥1.501.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Overvalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 117.37.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥102.19 in its last earnings report, beating expectations of ¥100.689. Following the earnings report the stock price went down -1.122%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation manages an extensive network of drugstores throughout Japan. The company operates a significant 1,130 retail locations, strategically positioned across the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. Established in 1983, its primary office is situated in Fukuoka, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Options Prices
Currently, No data available
---